Pacira BioSciences Inc logo

Pacira BioSciences Inc

PCRX
Healthcare|Drug Manufacturers - Specialty & Generic|USA
$25.47
-0.01 (-0.04%)
DCF (FCF)
$43.62
Tangible Book
$7.15
Graham Number
$18.67
Earnings Power
$19.49

About

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Stock Price

+7.5%(1Y)

Pipeline Summary

152 total trials
20
Phase 1
33
Phase 2
33
Phase 3
40
Phase 4
Completed: 101Terminated: 23Active: 4Recruiting: 8Withdrawn: 7NOT_YET_RECRUITING: 2ENROLLING_BY_INVITATION: 4Unknown: 3

Active Trials (12)

Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
NCT06340451Spasticity, Cerebral or Spinal Condition
N/AActive
Enrollment: 132 participants
Cryoneurolysis of the Suprascapular Nerve for Perioperative Pain Control After Receiving a Reverse Total Shoulder Arthroplasty (RTSA)
NCT07125833Degenerative Joint Disease of Shoulder
N/ARecruiting
Enrollment: 20 participants
The Effect of Pre-Operative Cryoneurolysis on Post-Operative Narcotic Consumption in Patients Undergoing Autograft ACL Reconstruction
NCT06603051ACL Repair
N/ARecruiting
Enrollment: 20 participants
Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System
NCT06958289Spasticity as Sequela of Stroke
N/ARecruiting
Enrollment: 25 participants
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
NCT07214844Low Back Pain, Chronic
N/ARecruiting
Enrollment: 110 participants
View all 12 active trials →

BioScore

5.5/10
Watchlist

Ownership

Recent Insider Trades

RIKER LAURENSELL
2026-06-116,115 shares @ $23.5
WILLIAMS KRISTENSELL
2026-06-0410,259 shares @ $22.27
Cross ShawnSELL
2026-04-2312,941 shares @ $25.16
Cross ShawnSELL
2026-04-2212,059 shares @ $25.09
SLONIN JONATHANSELL
2026-03-173,261 shares @ $22.82

Recent News

2026-07-01 12:43:14
2026-06-30 13:02:09
2026-06-13 04:00:21
Data last updated: Jul 12, 2026, 07:35 PM